TargetMol

Piritrexim

Product Code:
 
TAR-T24644
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T24644-1mg1mg£352.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T24644-5mg5mg£850.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T24644-10mg10mg£1,034.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T24644-25mg25mg£1,348.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T24644-50mg50mg£1,661.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T24644-100mg100mg£2,079.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
Piritrexim is a lipid-soluble dihydrofolate reductase inhibitor.
CAS:
72732-56-0
Formula:
C17H19N5O2
Molecular Weight:
325.372
Pathway:
DNA Damage/DNA Repair|Cell Cycle/Checkpoint|Metabolism
Purity:
0.98
SMILES:
COc1ccc(OC)c(Cc2cnc3nc(N)nc(N)c3c2C)c1
Target:
DHFR

References

1. Sigel CW, Macklin AW, Woolley JL Jr, Johnson NW, Collier MA, Blum MR, Clendeninn NJ, Everitt BJ, Grebe G, Mackars A, et al. Preclinical biochemical pharmacology and toxicology of piritrexim, a lipophilic inhibitor of dihydrofolate reductase. NCI Monogr. 1987;(5):111-20. PubMed PMID: 3431588. 2. Rosowsky A, Mota CE, Wright JE, Queener SF. 2,4-Diamino-5-chloroquinazoline analogues of trimetrexate and piritrexim: synthesis and antifolate activity. J Med Chem. 1994 Dec 23;37(26):4522-8. PubMed PMID: 7799402. 3. de Vries EG, Gietema JA, Workman P, Scott JE, Crawshaw A, Dobbs HJ, Dennis I, Mulder NH, Sleijfer DT, Willemse PH. A phase II and pharmacokinetic study with oral piritrexim for metastatic breast cancer. Br J Cancer. 1993 Sep;68(3):641-4. PubMed PMID: 8353055; PubMed Central PMCID: PMC1968400. 4. Lassiter LK, Tummala MK, Hussain MH, Stadler WM, Petrylak DP, Carducci MA. Phase II open-label study of oral piritrexim in patients with advanced carcinoma of the urothelium who have experienced failure with standard chemotherapy. Clin Genitourin Cancer. 2008 Mar;6(1):31-5. doi: 10.3816/CGC.2008.n.005. PubMed PMID: 18501080.